Stocks analysis

ABT vs ADBE Stock Comparison

Scores Breakdown

Metric ABT ADBE
📈 Growth 22/30 28/30
💰 Profitability 17/20 18/20
🏦 Financial Health 15/20 14/20
💵 Valuation 12/20 14/20
⚠️ Risk (lower is better) 4/10 6/10
Overall Score 72/100 78/100

Side-by-Side Summaries

ABT Analysis ADBE Analysis

📈 Growth & Financial Trajectory

Over the 8-quarter window, Revenue gravitated around $9.96B to $11.16B, ending at $11.16B in 2026 Q1, a start-to-end rise of about $1.2B (~12%). Net income remained positive through most quarters, with modest-to-strong fluctuations; several quarters show mid-single-digit billions in income, with notable variability from one-off items (e.g., tax effects).

💰 Margins & Cash Flow

Gross Margin was solid, around 56% on average (Gross Profit ~6.3B vs Revenues ~11.2B in 2026 Q1). Operating margin ranged roughly from 12% to 18%, peaking in 2025 Q2. Net cash flow from operating activities was consistently positive (e.g., 2026 Q1: $1.315B; prior quarters in the 1.4–2.9B range), while investing activities were typically cash outflows and financing modest.

🛡️ Balance Sheet & Liquidity

Total assets approximate $72B–$110B over the period with equity in the low-to-mid $50B range. The company shows a healthy current ratio (1.3–1.5) and modest long-term debt ($14–19B), supporting liquidity and balance sheet resilience.

⚠️ Key Drivers & Risks

  • Drivers: (1) Pharma/medical devices demand; (2) diversified product mix and recurring revenue from Rx/OTC portfolios.
  • Risks: (1) Regulatory/tax volatility and pricing pressure; (2) macro-cycle sensitivity and currency exposure.

📈 Growth & Financial Trajectory

Eight quarters show a steady top-line advance from about Revenues of $5.31B to about $6.62B, a roughly 25% gain. Net income remained resilient around $1.7–$1.9B, with modest quarterly swings. The company sustained strong operating margins aided by high gross margin discipline, underscoring durable profitability across periods.

💰 Margins & Cash Flow

Gross margin stayed in the high-80s, supporting healthy operating income of roughly $2.0–$2.4B on $5.3–$6.6B in Revenues. Net cash flow from operating activities tended positive around $2–3B per quarter, while investing/financing activities produced meaningful outflows, leading to periodic negative overall cash flow. Cash balances ranged ~$5–8B, with a gradual but modest decline as capital deployment evolved.

🛡️ Balance Sheet & Liquidity

Total assets sit near $29–30B with liabilities around $18–18.5B and equity near $11.5B, signaling solid capitalization. The near-term liquidity position shows a tighter profile: current assets ~ $9.0B vs current liabilities ~ $12.0B. Cash reserves provide liquidity, though aggregate cash declined in later quarters due to investing/financing activity.

⚠️ Key Drivers & Risks

  • Drivers: AI-enabled features in Creative Cloud; ongoing subscription growth and enterprise adoption.
  • Risks: Valuation sensitivity to growth trajectory; macro/enterprise spending cycles; competitive pressure in creative software.